2026 Q1 -tulosraportti
28 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,11%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 220 000 | NRD | NRD | ||
| 2 578 | - | - | ||
| 170 | - | - | ||
| 500 | - | - | ||
| 6 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·18 min sittenThis is AI, so take it with a grain of salt: A company should repurchase its own stock when its shares are undervalued and it has excess cash after funding all profitable expansion and R&D. Buying back stock is sensible when organic growth opportunities are limited and M&A (acquiring competitors) is too expensive, risky, or dilutive to shareholder value Can one draw the conclusion that management at least considers the stock to be undervalued? What counterarguments can one come up with,?
·6 t sittenI believe that Novo will rise quite nicely over the summer. Partly due to an upcoming correction, and partly due to hedge funds' shift of investments to healthcare in general. They are already underway according to Frank Hvid. Furthermore, Novo earns quite a lot of money, and with a P/E of 10, this will in itself lead to future price increases. Patience is a virtue. And yes, future results of their tests can affect the price in both directions. But historically, Novo performs well developmentally, so I believe that will also continue…not least in the long run. Remember, this is not a recommendation to buy or sell the stock.
·5 t sittenA few days before Wegovy was approved in the USA for obesity treatment, the share stood at 265. Now, with an outcry, slightly over 270. Even if the entire Wegovy and obesity treatment were to go bust, how much should the share be at? 250? Rising from there, like a good old healthcare company? What is likely for Wegovy? Complete collapse before 2026 is over? Hardly. Again, one is left with a solid company, at least with a 5-15 year investment horizon. With annual dividends. With a good moat. I am most concerned for traders who expect profit per month. And of course, those who bought the majority of their shares at 1000 dkk. The rest of us have bought a company, not a share
·7 t sittenTomorrow the NN stock makes a small comeback. I expect a 3-4% increase. What goes down without reason goes up and vice versa. Good luck! 🔥·14 min sittenOpens a bit lower. We'll have to see if the price stays above 270.
·8 t sittenNovo currently has a P/E of 10 and is raking in tons of money. The last financial report was excellent, but one must be careful not to believe that the market (especially the American one) behaves logically or fairly. Just look at the Tesla stock over the last year or so. Never have I seen such a profitable and rock-solid company paired with such a ridiculously low stock price as Novo Nordisk currently has. A P/E of 10 means that Novo earns so much money that it would only take the company 10 years to earn as much money as ALL Novo shares in circulation are worth together at the time of writing, which is an enormous number. Now is the time to get in, if you don't already own Novo shares, because the price makes absolutely no sense given how well the company is doing.
·9 t sitten · MuokattuWe must admit! The villain is USA - can be seen in posts. It's not about Novo perhaps not being so strong. Quite a lot, however, have expressed great skepticism,, after today's fall. Understandable - but there is always one’ who convinces the shareholders about USA, as the most despicable enemy.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
28 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,11%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18 min sittenThis is AI, so take it with a grain of salt: A company should repurchase its own stock when its shares are undervalued and it has excess cash after funding all profitable expansion and R&D. Buying back stock is sensible when organic growth opportunities are limited and M&A (acquiring competitors) is too expensive, risky, or dilutive to shareholder value Can one draw the conclusion that management at least considers the stock to be undervalued? What counterarguments can one come up with,?
- ·6 t sittenI believe that Novo will rise quite nicely over the summer. Partly due to an upcoming correction, and partly due to hedge funds' shift of investments to healthcare in general. They are already underway according to Frank Hvid. Furthermore, Novo earns quite a lot of money, and with a P/E of 10, this will in itself lead to future price increases. Patience is a virtue. And yes, future results of their tests can affect the price in both directions. But historically, Novo performs well developmentally, so I believe that will also continue…not least in the long run. Remember, this is not a recommendation to buy or sell the stock.·5 t sittenA few days before Wegovy was approved in the USA for obesity treatment, the share stood at 265. Now, with an outcry, slightly over 270. Even if the entire Wegovy and obesity treatment were to go bust, how much should the share be at? 250? Rising from there, like a good old healthcare company? What is likely for Wegovy? Complete collapse before 2026 is over? Hardly. Again, one is left with a solid company, at least with a 5-15 year investment horizon. With annual dividends. With a good moat. I am most concerned for traders who expect profit per month. And of course, those who bought the majority of their shares at 1000 dkk. The rest of us have bought a company, not a share
- ·7 t sittenTomorrow the NN stock makes a small comeback. I expect a 3-4% increase. What goes down without reason goes up and vice versa. Good luck! 🔥·14 min sittenOpens a bit lower. We'll have to see if the price stays above 270.
- ·8 t sittenNovo currently has a P/E of 10 and is raking in tons of money. The last financial report was excellent, but one must be careful not to believe that the market (especially the American one) behaves logically or fairly. Just look at the Tesla stock over the last year or so. Never have I seen such a profitable and rock-solid company paired with such a ridiculously low stock price as Novo Nordisk currently has. A P/E of 10 means that Novo earns so much money that it would only take the company 10 years to earn as much money as ALL Novo shares in circulation are worth together at the time of writing, which is an enormous number. Now is the time to get in, if you don't already own Novo shares, because the price makes absolutely no sense given how well the company is doing.
- ·9 t sitten · MuokattuWe must admit! The villain is USA - can be seen in posts. It's not about Novo perhaps not being so strong. Quite a lot, however, have expressed great skepticism,, after today's fall. Understandable - but there is always one’ who convinces the shareholders about USA, as the most despicable enemy.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 220 000 | NRD | NRD | ||
| 2 578 | - | - | ||
| 170 | - | - | ||
| 500 | - | - | ||
| 6 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
28 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,11%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18 min sittenThis is AI, so take it with a grain of salt: A company should repurchase its own stock when its shares are undervalued and it has excess cash after funding all profitable expansion and R&D. Buying back stock is sensible when organic growth opportunities are limited and M&A (acquiring competitors) is too expensive, risky, or dilutive to shareholder value Can one draw the conclusion that management at least considers the stock to be undervalued? What counterarguments can one come up with,?
- ·6 t sittenI believe that Novo will rise quite nicely over the summer. Partly due to an upcoming correction, and partly due to hedge funds' shift of investments to healthcare in general. They are already underway according to Frank Hvid. Furthermore, Novo earns quite a lot of money, and with a P/E of 10, this will in itself lead to future price increases. Patience is a virtue. And yes, future results of their tests can affect the price in both directions. But historically, Novo performs well developmentally, so I believe that will also continue…not least in the long run. Remember, this is not a recommendation to buy or sell the stock.·5 t sittenA few days before Wegovy was approved in the USA for obesity treatment, the share stood at 265. Now, with an outcry, slightly over 270. Even if the entire Wegovy and obesity treatment were to go bust, how much should the share be at? 250? Rising from there, like a good old healthcare company? What is likely for Wegovy? Complete collapse before 2026 is over? Hardly. Again, one is left with a solid company, at least with a 5-15 year investment horizon. With annual dividends. With a good moat. I am most concerned for traders who expect profit per month. And of course, those who bought the majority of their shares at 1000 dkk. The rest of us have bought a company, not a share
- ·7 t sittenTomorrow the NN stock makes a small comeback. I expect a 3-4% increase. What goes down without reason goes up and vice versa. Good luck! 🔥·14 min sittenOpens a bit lower. We'll have to see if the price stays above 270.
- ·8 t sittenNovo currently has a P/E of 10 and is raking in tons of money. The last financial report was excellent, but one must be careful not to believe that the market (especially the American one) behaves logically or fairly. Just look at the Tesla stock over the last year or so. Never have I seen such a profitable and rock-solid company paired with such a ridiculously low stock price as Novo Nordisk currently has. A P/E of 10 means that Novo earns so much money that it would only take the company 10 years to earn as much money as ALL Novo shares in circulation are worth together at the time of writing, which is an enormous number. Now is the time to get in, if you don't already own Novo shares, because the price makes absolutely no sense given how well the company is doing.
- ·9 t sitten · MuokattuWe must admit! The villain is USA - can be seen in posts. It's not about Novo perhaps not being so strong. Quite a lot, however, have expressed great skepticism,, after today's fall. Understandable - but there is always one’ who convinces the shareholders about USA, as the most despicable enemy.
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 220 000 | NRD | NRD | ||
| 2 578 | - | - | ||
| 170 | - | - | ||
| 500 | - | - | ||
| 6 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt